On the contrary, analysis from ACROSTUDY reveals that patients with DM require higher pegvisomant (PEGV) doses to normalize IGF-1 [104]; this is explained by the fact that mean HbA1c among diabetic patients in this study is 7%, reflecting an hyperinsulinemic DM phenotype, due to either endogenous or exogenous insulin [104]. The gene discussed is IGF1; the disease is diabetes mellitus.